Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

Abstract The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient access to these therapies. There is currently a need to define and comply...

Full description

Bibliographic Details
Main Authors: Judith Steinberg, Yara D. Fragoso, Juan Carlos Duran Quiroz, Juan Raul García, Caroline Guerra, Virginia Rodriguez, Claudia Carcamo Rodriguez, Ethel Ciampi, Edgar Correa-Diaz, Miguel Macías, Nelson Novarro, Darwin Vizcarra, Carlos Oehninger Gatti, Geraldine Orozco, Adriana Carrá
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-05-01
Series:Neurology and Therapy
Subjects:
Alemtuzumab
Biosimilar
Biological drugs
Glatiramoids
Interferon beta
Multiple sclerosis
Online Access:http://link.springer.com/article/10.1007/s40120-019-0139-y

Internet

http://link.springer.com/article/10.1007/s40120-019-0139-y

Similar Items